drugset / Trial / NCT05329155
Early Administration of Heparin At FMC for PPCI of STEMI Patients
Completed
1145 enrolled
Renmin Hospital of Wuhan University
Anlu People's Hospital · collabCR & WISCO General Hospital · collabCaidian People's Hospital · collabChibi General Hospital · collabEzhou Central Hospital · collabFifth Hospital in Wuhan · collabGeneral Hospital of Yangtze River shipping · collabGuoyao Dongfeng General Hospital · collabHanyang University · collabHubei University of Medicine · collabHubei Zhongshan Hospital · collabJiangling People's Hospital · collabJiangxia First People's Hospital · collabJingzhou Central Hospital · collabLaohekou First Hospital · collabPeople's Hospital of Jingshan · collabPeople's Hospital of Tongcheng · collabShiyan People's Hospital · collabSongzi People's Hospital · collabThe Central Hospital of Enshi Tujia And Miao Autonomous Prefecture · collabThe Central Hospital of Huanggang · collabTianmen First People's Hospital · collabWuhan Central Hospital · collabWuhan Hospital of Traditional Chinese Medicine · collabWuhan No.1 Hospital · collabWuhan No.6 Hospital · collabWuhan Puren Hospital · collabWuhan Third Hospital · collabWuxue First People's Hospital · collabXiangyang Central Hospital · collabXianning Central Hospital · collabXianning First People's Hospital · collabXiantao First People's Hospital · collabXishui People's Hospital · collabYichang Central People's Hospital · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Heparin is the first choice of anticoagulation drug for primary PCI of STEMI patients. However, the priority of use of hepairn in first medical contact or in Cathlab has not yet studied. Previous study revealed early use of antithrombotic drugs could improve patient's survival. Here we supposed that use of heparin at first medical contact could increase the TIMI flow 3 grade ratio in STEMI patients and improve patient's survival and/or reduce MACE rather than in Cathlab.
Timeline
- Start
- 2022-07-20
- Primary completion
- 2023-08-20
- Completion
- 2024-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Heparin | Other / unclassified | 100 iu/kg | Intravenous |